Emergent BioSolutions Files 8-K on Shareholder Votes & Financials
Ticker: EBS · Form: 8-K · Filed: May 6, 2025 · CIK: 1367644
| Field | Detail |
|---|---|
| Company | Emergent Biosolutions Inc. (EBS) |
| Form Type | 8-K |
| Filed Date | May 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, sec-filing
Related Tickers: EBS
TL;DR
Emergent BioSolutions (EBS) filed an 8-K on April 30, 2025, covering shareholder votes and financials.
AI Summary
Emergent BioSolutions Inc. filed an 8-K on May 6, 2025, reporting on matters submitted to a vote of security holders and financial statements as of April 30, 2025. The filing details their corporate structure, including their state of incorporation (Delaware) and fiscal year end (December 31).
Why It Matters
This filing provides an update on key corporate governance and financial reporting for Emergent BioSolutions, which is important for investors to understand the company's current status.
Risk Assessment
Risk Level: low — This is a routine filing for corporate reporting and does not contain new material events or financial performance data.
Key Numbers
- 001-33137 — SEC File Number (Identifies the company's filing history with the SEC.)
- 14-1902018 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Emergent BioSolutions Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- April 30, 2025 (date) — Date of earliest event reported
- May 6, 2025 (date) — Filing date
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that 'Submission of Matters to a Vote of Security Holders' is an item covered, but the specific details of these matters are not provided in the excerpt.
What financial statements are included in this filing?
The filing states 'Financial Statements and Exhibits' are included, but the excerpt does not detail the specific financial statements provided.
When is Emergent BioSolutions' fiscal year end?
Emergent BioSolutions' fiscal year ends on December 31.
What is the principal executive office address for Emergent BioSolutions?
The principal executive offices are located at 300 Professional Drive, Gaithersburg, Maryland 20879.
Under which section of the Securities Exchange Act is this report filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 6, 2025 regarding Emergent BioSolutions Inc. (EBS).